Bilacad Dex Syrup – is specifically formulated for Comprehensive Respiratory Relief. Cadila Pharmaceuticals Limited has announced the launch of this, to address the increasing burden of respiratory and allergy-related conditions.
Ahmedabad: Cadila Pharmaceuticals Limited, one of India’s most respected and innovation-driven pharmaceutical companies, has announced the launch of Bilacad Dex Syrup, to address the increasing burden of respiratory and allergy-related conditions with a novel fixed-dose combination of Bilastine, Dextromethorphan, and Phenylephrine.
A Triple-Action Innovation for Modern Respiratory Care
Bilacad Dex Syrup is specifically formulated to target multiple symptoms associated with the common cold and allergic rhinitis, including cough, nasal congestion, and allergic manifestations such as sneezing and itching. Its three active pharmaceutical ingredients work in synergy to deliver rapid and sustained relief:
• Bilastine (3.3 mg per 5ml) – A second-generation, non-sedating antihistamine known for its high selectivity for peripheral H1 receptors. It effectively manages allergic symptoms without causing drowsiness, making it ideal for daytime use and improving patient adherence.
• Dextromethorphan Hydrobromide (10 mg per 5ml) – A centrally acting antitussive that suppresses the cough reflex at the medullary level, providing relief from persistent, dry cough without impairing respiratory function.
• Phenylephrine Hydrochloride (5 mg per 5ml) – A selective alpha-adrenergic receptor agonist that reduces nasal swelling through vasoconstriction, offering targeted decongestion without stimulating the central nervous system.
Bilacad Dex Syrup represents Cadila Pharmaceuticals’ strategic expansion into combination therapies that cater to the evolving needs of patients and prescribers seeking efficient multi-symptom relief. It is poised to make a meaningful impact in the ₹4,709 crore Indian cough syrup market.
Backed by Clinical Evidence
A recent open-label, randomized, multicenter clinical trial comparing the Bilastine-Dextromethorphan-Phenylephrine (BDP) combination with a leading competitor demonstrated non-inferiority in efficacy and safety. Subjects reported significant improvement in cough and nasal symptoms without sedation, affirming Bilacad Dex Syrup’s suitability for both adults and adolescents.
The trial’s findings, published in Cureus (DOI: 10.7759/cureus.75836), support the use of this combination as an effective and safe alternative to older sedative antihistamine-based treatments.
Meeting Patient Needs in a Fast-Paced World
With growing awareness around the side effects of sedating antihistamines and the need for convenience, Bilacad Dex Syrup aligns with contemporary healthcare preferences. It is designed for oral administration and is indicated for adults and children aged 12 years and above, at a dosage of 10 ml three times daily. The syrup is well tolerated in elderly populations, and its use is not recommended for children under 12 for more than 7 days.
Moreover, Bilacad Dex is especially suitable for professionals, students, and active individuals who seek effective symptom relief without compromising alertness and productivity.
Strengthening CPL’s Respiratory & Allergy Portfolio
CPL’s growing therapeutic footprint across anti-infectives, respiratory care, and primary healthcare. The introduction of Bilacad Dex Syrup marks Cadila Pharmaceuticals’ expanding space of combination therapies designed for upper respiratory tract infections and seasonal/perennial allergy management.
Speaking on the launch, a senior spokesperson from CPL said, “With Bilacad Dex Syrup, we are offering physicians and patients a scientifically validated, non-sedating, and all-in-one solution for respiratory discomfort and allergic symptoms. This product reflects our ongoing commitment to innovation, affordability, and patient well-being.”
Safety and Usage in Special Populations
While Bilacad Dex is generally well tolerated, caution is advised in certain populations:
• Pregnancy & Lactation: As a precautionary measure, its use is not recommended during pregnancy or breastfeeding.
• Contraindications: It should not be administered to patients with known hypersensitivity to any of the ingredients.
• Elderly patients (65+): No dosage adjustment is necessary.
Availability
Bilacad Dex Syrup will be made available across India through CPL’s extensive distribution network, reaching urban and semi-urban markets. Its accessible pricing strategy reflects Cadila Pharmaceuticals’ ongoing vision to make high-quality healthcare more affordable and patient-friendly.
